Insights

What You Need to Know About Our Newly Added Commercial API Manufacturing Capacity

​About our recently announced joint venture with CENRA API Solutions/CCSB, our President of Global CMC, Mr. Yaohui Ji, shared insights on what this newly added capability means for our customers. It offers a flexible, coordinated approach with unified quality systems, regulatory readiness, and support across small molecules, peptides, and fermentation products, combining technical depth with agility to help programs scale from development to commercial production.
March 17, 2026

Predicting Accurately to De-Risk Early Development

​An exposure-driven, translational approach, linking early ADME with biomarker discovery, can help teams define the therapeutic window long before lead candidate nomination, according to Hong Wan from BioDuro.
February 11, 2026

BioDuro Advances DNA-Encoded Peptide Libraries: 108-Channel Automation Enables 10-mer+ DNA-Encoded Macrocycles for High-Throughput Drug Discovery

BioDuro has developed a 108-channel automated solid-phase peptide synthesis system that produces oligopeptide building blocks with approximately 90% crude purity, enabling construction of DNA-encoded libraries featuring 10-mer+ macrocyclic peptides. This capability addresses a critical bottleneck in DEL peptide technology -- the historical limitation to short peptide lengths -- while maintaining compatibility with the split-and-pool synthesis workflow that enables library sizes reaching billions of compounds.
February 08, 2026

Stop Bottlenecks Before They Happen: Early-Stage Drug Development Tips

This article, with insights from Subas Sakya, Chief Scientific Officer, BioDuro, was originally published in the Chimica Oggi-Chemistry Today, Vol. 43(5), pages 71-72.
October 30, 2025

Fragment-Based Drug Discovery: A Unified Workflow for Efficient Lead Generation

This article, with insights from Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division, BioDuro, was originally published in the DDW Fall 2025, pages 30-31.
September 30, 2025

An interview with John Liu: From DIO (diet-induced obesity) Models to Patients: Accelerating the Next Generation of Obesity Drugs

GLP-1 drugs like semaglutide and tirzepatide have demonstrated significant weight loss and improved metabolic profiles. However, a major clinical challenge is weight rebound after treatment ends. Tria
September 19, 2025

Q&A:In Vitro Evaluation for STAT6 Degraders, Using Kymera's Patented Molecule as an Example

To uncover the story behind one of the most promising frontiers in immunology and drug discovery, we sat down with Lin Teng, PhD, head of Biology Department at BioDuro. Her team played a key role in developing and validating an advanced STAT6 PROTAC evaluation platform—accelerating the journey from patent to preclinical proof. Below is a brief Q&A that highlights some of the exciting developments and challenges in targeting STAT6 using PROTACs.
July 14, 2025

Solid-Phase or Liquid-Phase? How Has Peptide Synthesis Revolutionized Drug Discovery?

This article, with insights from Yuyan Chen, Director of Medicinal Chemistry, BioDuro, was originally published in the European Biopharmaceutical Review, Summer 2025,pages 54-56. Visit the websit
June 18, 2025
Total 26 1234
✉️Contact Us
We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all